Sino Biopharmaceutical
Sino Biopharmaceutical Limited, commonly referred to as Sino Biopharm, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Founded in 1997, the company has established a strong presence across major operational regions, including Mainland China and various international markets. Sino Biopharm focuses on the research, development, manufacturing, and marketing of innovative medicines, particularly in the fields of oncology, cardiovascular diseases, and infectious diseases. With a robust portfolio of core products, Sino Biopharm distinguishes itself through its commitment to high-quality standards and advanced biopharmaceutical technologies. The company has achieved significant milestones, including numerous product approvals and a growing market share, positioning itself as a key contributor to the healthcare landscape. Notably, Sino Biopharm's dedication to innovation and patient-centric solutions has earned it recognition as a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does Sino Biopharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sino Biopharmaceutical's score of 34 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sino Biopharmaceutical's reported carbon emissions
In 2023, Sino Biopharmaceutical reported total greenhouse gas emissions of approximately 239,239,610 kg CO2e, comprising 17,046,220 kg CO2e from Scope 1 and 222,193,400 kg CO2e from Scope 2 emissions. This marks a slight increase in emissions compared to 2022, where total emissions were about 277,084,360 kg CO2e, with Scope 1 at 16,093,260 kg CO2e and Scope 2 at 260,991,100 kg CO2e. The company has set a near-term target to reduce greenhouse gas emissions intensity by 20% per RMB 1 million of revenue by 2025, using 2021 as the baseline year. This commitment reflects Sino Biopharmaceutical's proactive approach to managing its carbon footprint and aligns with industry standards for climate action. Sino Biopharmaceutical does not currently report Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. The emissions data is not cascaded from any parent organization, ensuring that the figures are specific to Sino Biopharmaceutical Limited. Overall, Sino Biopharmaceutical is taking significant steps towards reducing its carbon emissions and enhancing its sustainability practices in the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 21,711,730 | 00,000,000 | 00,000,000 |
| Scope 2 | 253,214,050 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sino Biopharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
